Microvascular Disease in Type 1 Diabetes
|
|
- Opal Campbell
- 6 years ago
- Views:
Transcription
1 Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
2 The Course of Type 1 Diabetes 100% Genetic Susceptibility Inciting Event(s) Silent Cell Loss Diabetes Onset Total Diabetes Islet Cell Mass 50% Complications 0% Time (years)
3 Burden of Diabetes Diabetic Retinopathy #1 Cause of Blindness in Working Age Adults Diabetic Nephropathy #1 Cause of End Stage Renal Disease Diabetic Amputations # 1 Cause of Non-traumatic Lower Extremity Amputations Diabetic Vascular Disease 2-to-6-Fold More Likely to Have Heart Disease National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011 Available at:
4 DRS: Cumulative Rates of Severe Visual Loss From Proliferative Diabetic Retinopathy 40 Control Event Rates/ Treated Follow-up (Months) Ophthalmology 1981;88:
5 DCCT
6 A1c During DCCT DCCT Intervention Conventional mean A1c 9.1% 9 A1c (%) Intensive mean A1c 7.2% Study Year
7 DCCT Retinopathy Progression Primary Prevention Cohort 100% Cumulative Incidence (%) 80% 60% 40% 20% 0% p< Years Conventional Group Intensive Group DCCT. NEJM 1993; 329:977
8 DCCT Retinopathy Progression Secondary Intervention Cohort 100% Cumulative Incidence (%) 80% 60% 40% 20% 0% p< Years Conventional Group Intensive Group DCCT. NEJM 1993; 329:977
9 DCCT: Microalbuminuria & Macroalbuminuria Primary Prevention Cohort Percentage of Patients Conventional Intensive Microalbuminuria > 40 mg/24 h Albuminuria 300 mg/24 h P< 0.04 P= Year of Study DCCT (1993) NEJM 329:
10 DCCT: Microalbuminuria and Macroalbuminuria Secondary Intervention Cohort Percentage of Patients Conventional Intensive Microalbuminuria 40 mg/24 h P= P= 0.01 Albuminuria 300 mg/24 h Year of Study DCCT (1993) NEJM 329:
11 DCCT-EDIC
12 A1c During DCCT and EDIC 11 DCCT Intervention Conventional mean A1c 9.1% Training EDIC Observation 10 9 Conventional mean A1c 8.2% A1c (%) Intensive mean A1c 7.2% Intensive mean A1c 8.0% Study year EDIC = Epidemiology of Diabetes Interventions and Complications Nathan DM, et al. N Engl J Med 2005;353;
13 Distribution of A1c in the Former DCCT Intensive & Conventional Groups During EDIC Conventional Intensive A1c (%) p < DCCT Closeout EDIC year JAMA 2003; 290:
14 HbA1c by DCCT Treatment Group at the end of the DCCT and at Each of the First 10 years of EDIC DCCT-EDICResearch Group, Arch Ophthalmol 2008;126:
15 Cumulative incidence of further 3-step progression of retinopathy from DCCT closeout to EDIC study year 10 (adjusted for retinopathy level at DCCT end, cohort, entry HbA1c, baseline diabetes duration) DCCT-EDICResearch Group, Arch Ophthalmol 2008;126:
16 Cumulative incidence of proliferative retinopathy or worse from DCCT closeout to EDIC study year 10 (adjusted for retinopathy level at DCCT end, cohort, entry HbA1c, baseline diabetes duration) DCCT-EDICResearch Group, Arch Ophthalmol 2008;126:
17 Clinic vs Real-world Data: Incidence of Proliferative Retinopathy (DCCT-EDIC/EDC) Cumulative Incidence (%) Diabetes Duration (years) DCCT Conventional therapy EDC DCCT Intensive therapy Cumulative incidence of proliferative retinopathy or worse DCCT/EDIC Research Group. Arch Intern Med 2009;69:
18 Prevalence of Diabetic Retinopathy in Type 1 Diabetes Wisconsin Epidemiological Study of Diabetic Retinopathy: WESDR Prevalence (%) Any Retinopathy Proliferative Retinopathy Duration of Diabetes (years) Klein R, et al, Arch Ophthalmol ;102:
19 Cumulative Incidence of Severe Retinopathy in Childhood T1D According To Long-Term Glycemia 80 Cumulative Proportion (%) Linkoping HbA1c < 7.6% HbA1c % HbA1c % HbA1c 9.6% ** Duration of Diabetes (years) Nordwall et al. Ped Diab 2009;10:168-76
20 Cumulative Incidence of Laser-Rx Rx d d DR in T1D with Onset Age < 15 Years, According To Year of Onset 70 Linkoping Cumulative Proportion (%) Overall p = Duration of Diabetes (years) Nordwall et al. Diabetologia 2004;47:
21 Retinopathy Diabetes is leading cause of new cases of blindness among adults ages years Of people with diabetes aged 40 years, 4.2 million (28.5%) had diabetic retinopathy in ,000 (4.4% of those with diabetes) had advanced diabetic retinopathy that could lead to severe vision loss (15.7% of those with retinopathy) National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011 Available at:
22 Cumulative Incidence of New Microalbuminuria > 40 mg/24 h During EDIC Cumulative Incidence (%) % risk reduction p <.0001 Conventional Intensive EDIC Year JAMA 2003; 290:
23 Cumulative Incidence of New Clinical Albuminuria > 300 mg/24 h During EDIC Cumulative Incidence (%) % risk reduction p <.0001 Conventional Intensive EDIC Year JAMA 2003; 290:
24 Estimated GFR over Time DCCT/EDIC Research Group. N Engl J Med 2011;365:
25 Cumulative Incidence of an Impaired Glomerular Filtration Rate, According to Treatment Group. DCCT/EDIC Research Group. N Engl J Med 2011;365:
26 Impaired GFR Can Develop Without Albuminuria Cumulative Incidence Albuminuria Status Time from randomization (years) 10 0 Normo Micro Macro Molitch M et al, Diabetes Care 2010
27 Glycemic Control Prevents Albuminuria de Boer IH et al, Arch Int Med 2011
28 Microalbuminuria Can Regress de Boer IH et al, Arch Int Med 2011
29 Clinic vs Real-world Data: Incidence of Nephropathy (DCCT-EDIC/EDC) Cumulative incidence, % DCCT Conventional therapy EDC DCCT Intensive therapy Diabetes duration, years Nephropathy defined as albumin excretion rate 300 mg/24 h, serum Cr 2 mg/dl, dialysis or renal transplant DCCT/EDIC Research Group. Arch Intern Med 2009; 169:
30 Cumulative Incidence of the First of Any of the Predefined CVD Outcomes Cumulative Incidence of Any Predefined CV Outcome Risk reduction 42% 95% CI: Log-rank p=0.016 Conventional treatment Intensive treatment No. at Risk Years Since Entry Intensive Conventional Nathan DM, et al. N Engl J Med 2005;353;
31 Cumulative Incidence of the First Occurrence of Non-fatal MI, Stroke, or Death from CVD Cumulative Incidence of Non-fatal MI, Stroke, or Death from CVD Risk reduction 57% 95% CI: Log-rank p=0.018 Conventional treatment Intensive treatment No. at Risk Years Since Entry Intensive Conventional Nathan DM, et al. N Engl J Med 2005;353;
32 Clinic vs Real-world Data: Incidence of CVD (DCCT-EDIC/EDC) Cumulative incidence, % DCCT Conventional therapy EDC DCCT Intensive therapy Diabetes duration, years CVD was defined as: non-fatal myocardial infarction or stroke, CVD death, subclinical MI,, angina, angioplasty or coronary artery bypass DCCT/EDIC Research Group. Arch Intern Med 2009; 169:
33 DCCT: Absolute Risk of Severe Hypoglycemia by Mean A1c 120 Rate of severe Hypoglycemia (per 100 patient-years) DCCT: 1986 to Glycosylated Hemoglobin (%) DCCT. N Engl J Med 1993;329:977-86
34 Two Eras of Diabetes Management 120 Rate of severe Hypoglycemia (per 100 patient-years) JDRF CGM Study Control Group DCCT: 1986 to Glycosylated Hemoglobin (%) DCCT. N Engl J Med 1993;329: JDRF. N Engl J Med 2008;359:
35 What was different? Insulin Analogs!!
36 Ideal Basal/Bolus Insulin Absorption Pattern
37 Impact of Continuous Glucose Monitoring on Rate of Severe Hypoglycemia Compared to DCCT Rate of severe Hypoglycemia (per 100 patient-years) Age 25 years with A1C < 7.0% Age years with A1C < 7.0 % Age years with A1C < 7.0% Age 25 years with A1C 7.0% Age years with A1C 7.0% Age years with A1C 7.0% Glycosylated Hemoglobin (%) JDRF. N Engl J Med 2008;359:
38 Modern Approaches Can Achieve Meticulous Control Without Much Risk
39 Burden of Diabetes Diabetic Retinopathy #1 Cause of Blindness in Working Age Adults Diabetic Nephropathy #1 Cause of End Stage Renal Disease Diabetic Amputations # 1 Cause of Non-traumatic Lower Extremity Amputations Diabetic Vascular Disease 2-to-6-Fold More Likely to Have Heart Disease National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011 Available at:
40 Cumulative CAD Mortality In T1D 60 Males Cumulative Mortality (%) Females Joslin T1D Cohorts Framingham Cohorts Attained Age (years) Krolewski et al. Am J Cardiol 1987; 59:
41 Relative Mortality In T1D With and Without Proteinuria Women with proteinuria Men with proteinuria Relative Mortality Women without proteinuria Men without proteinuria Age (years) Borch-Johnsen et al Diabetologia 1985; 28:
42 Relative Mortality From CVD In T1D With and Without Proteinuria With proteinuria Without proteinuria Relative Mortality Diabetes Duration (years) Borch-Johnsen et al BMJ 1987; 294:
43 Cumulative Incidence CVD In T1D With and Without Proteinuria 40 Cumulative Incidence of Coronary Heart Disease (%) Years After Onset of Proteinuria Jensen et al. Diabetologia 1987; 30:
44 Diabetic Nephropathy and Mortality in Patients with Type 1 Diabetes 1.00 The FinnDiane Study 0.98 Normoalbuminuria Adjusted Survival (%) Microalbuminuria 0.90 Macroalbuminuria Duration of follow-up (years) Groop et al. Diabetes 2009; 58,
45 Diabetic Nephropathy and Mortality in Patients with Type 1 Diabetes The FinnDiane Study Groop et al. Diabetes 2009; 58,
46 Pittsburgh EDC 20-yr Mortality Risk in T1D Related to Renal Disease Unadjusted Survival (%) Normal MA ON ESRD Duration of follow-up (years) (%) Orchard et al. Diabetologia 2010;53:
47 Pittsburgh EDC 20-yr Mortality Risk in T1D Related to Renal Disease 40.0 Adjusted Hazard Ratio SMR Normoalbuminuria Microalbuminuria Overt Nephropathy ESRD Orchard et al. Diabetologia 2010;53:
48 Prevalence of Microalbuminuria in Children with T1D, in Relation to Mean Lifetime HbA 1 c Amin R, et al. BMJ 2008;336:
49 Cumulative Incidence of Overt Nephropathy In Childhood T1D According To Long-Term Glycemic Control 50 Linkoping 40 Cumulative Proportion (%) HbA1c <7.6% HbA1c % HbA1c % HbA1c 9.6% *** Duration of Diabetes (years) Nordwall et al. Ped Diab 2009; 10:
50 Incidence Rate of End-stage Renal Disease According To Time Period of Diagnosis of Type 1 Diabetes 10 Finland Incidence Rate, Cases Per 1000 Patients (years) * * * Period of Diagnosis of Type 1 Diabetes * Years After Diagnosis of Type 1 Diabetes Finne, P. et al. JAMA 2005;294:
51 Cumulative incidence of diabetic nephropathy in type 1 diabetes Denmark Cumulative incidence (%) Duration of diabetes (years) (n = 113) ( 1974 (n n = 130) ( 1979 (n n = 113) ( 1984 (n n = 244) Hovind et al. Diabetes Care 2003;26:
52 Cumulative Incidence of Nephropathy Among Patients In Whom T1D Began Before Age 15 Years, According To Year of Onset 50 Linkoping Overall p<0.001 Cumulative Proportion (%) Duration of Diabetes (years) Nordwall et al. Diabetologia 2004; 47:
53 All-Cause Mortality In T1D By Diagnosis Cohort - Pittsburgh Cumulative Survival Diabetes Duration At Death Pambianco et al Diabetes 2006; 55:
54 Modern Approaches Can Reduce Risk of Complications
55
DCCT Diabetes Control & Complications Trial
DCCT Diabetes Control & Complications Trial A. Vinik MD, PhD, FCP, MACP, FACE, Καθηγητής και Αντιπρόεδρος για την Έρευνα, Ιατρική Σχολή Ανατολικής Βιρτζίνια, Κέντρο Ενδοκρινολογικών και Μεταβολικών Νοσημάτων,
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationDR as a Biomarker for Systemic Vascular Complications
DR as a Biomarker for Systemic Vascular Complications Lihteh Wu MD Asociados de Mácula, Vítreo y Retina de Costa Rica San José, Costa Rica LW65@cornell.edu Disclosures Dr Wu has received lecture fees from
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationThe Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited
Diabetes Publish Ahead of Print, published online January 25, 2008 The Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited
More informationINTRODUCTION. In this study we examined the
GLYCEMIC CONTROL PREDICTS DIABETIC EXTRARENAL MICROVASCULAR COMPLICATIONS BUT NOT RENAL SURVIVAL IN PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE Background: Control of blood pressure (BP) and
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationSee accompanying articles, pp. 5, 8, 9, 17, 24, 31, and 44.
Diabetes Care Volume 37, January 2014 39 Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology Complications Study John M. Lachin, 1 Trevor J. Orchard,
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationHow complicated is diabetes? Jonathan Shaw
How complicated is diabetes? Jonathan Shaw Diabetic Complications Microvascular Complications Macrovascular Complications Diabetic Retinopathy Stroke Diabetic Nephropathy Heart Disease Diabetic Neuropathy
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationType 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival
Type 2 Diabetes Treat to: limit complications maintain quality of life Improve survival 1 Criteria for the diagnosis of diabetes 1. HbA1C 6.5% (rounded to 50mmol/mol). 2. FPG 7.0 mmol/l. 3. 2-h plasma
More informationSAIL documentation SUMMIT
SAIL documentation for use within SUMMIT Variable definitions for upload of individual level information on diabetic complications into Sample availabilty system (SAIL) 17 March 011 Introduction SAIL is
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationADVANCE Endpoints. Primary outcome. Secondary outcomes
ADVANCE Trial-NEJM 11,140 type 2 patients with h/o microvascular or macrovascular disease or 1 vascular disease risk factor Control A1c to 6.5% vs standard tx Intensive arm received gliclazide XL 30 to
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationAdolescent renal and cardiovascular disease protection in type 1 diabetes AdDIT Study
Keystone, Colorado, July 2013 Practical Ways to Achieve Targets in Diabetes Care Adolescent renal and cardiovascular disease protection in type 1 diabetes AdDIT Study Professor David Dunger Department
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationARTICLE. T. J. Orchard & A. M. Secrest & R. G. Miller & T. Costacou
Diabetologia (2010) 53:2312 2319 DOI 10.1007/s00125-010-1860-3 ARTICLE In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationComplications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley
Complications of Diabetes: Screening and Prevention Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley Diabetic Complications Microvascular: Retinopathy Nephropathy Neuropathy Macrovascular:
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationMORTALITY TRENDS IN A POPULATION-BASED TYPE 1 DIABETES COHORT. Aaron M. Secrest. B.S., Brigham Young University, 2003
MORTALITY TRENDS IN A POPULATION-BASED TYPE 1 DIABETES COHORT by Aaron M. Secrest B.S., Brigham Young University, 2003 M.P.H., University of Pittsburgh, 2008 Submitted to the Graduate Faculty of the Graduate
More informationDisclosure to Participants. Sharing Evidence-Based Hope: The Surprisingly Good News about Avoiding Diabetes Complications
Sharing Evidence-Based Hope: The Surprisingly Good News about Avoiding Diabetes Complications William H. Polonsky, PhD, CDE Richard M. Jackson, MD August 4, 2017 Disclosure to Participants Notice of Requirements
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDiabetic & Complications. Dr. A K Viswanath Consultant Diabetologist
Diabetic & Complications Dr. A K Viswanath Consultant Diabetologist Outline Challenges in diabetes How do we fare? Diabetes complications Improving outcomes in diabetes Types of Diabetes Type-1 DM Genetic
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationRisk Factors for CVD in Type 1 Diabetes
Risk Factors for CVD in Type 1 Diabetes Marian Rewers, MD, PhD Professor & Clinical Director, BDC Duality of Interest Declaration I have no conflict of interest in the field covered by my lecture but I
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationDiabetes Complications Update
Diabetes Complications Update George Grunberger, MD, FACP, FACE Chairman, Grunberger Diabetes Institute Clinical Professor, Internal Medicine and Molecular Medicine & Genetics Wayne State University School
More informationDiabetes outcomes Keystone 17 July 2014
Diabetes outcomes Keystone 17 July 214 How diabetes outcomes have changed over the past 3 years JBN: 194,119.11 Date of Prep: June 214 Professor Philip Home Newcastle University How diabetes outcomes have
More informationRETINOPATHY AND NEPHROPATHY IN PATIENTS WITH TYPE 1 DIABETES FOUR YEARS AFTER INTENSIVE THERAPY
RETINOPATHY AND NEPHROPATHY IN PATIENTS WITH TYPE 1 DIABETES FOUR YEARS AFTER A TRIAL OF INTENSIVE THERAPY THE DIABETES CONTROL AND COMPLICATIONS TRIAL/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationHIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1
Fernando Vega, MD HIHIM 409 July 31, 2008 Hyperglycemia characterized by relative or absolute lack of insulin secretion Varying degrees of insulin resistance Often associated with symptoms: polyruia, polydipsia,
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationOne of the most important questions in diabetes management
Special Feature and Commentary Does Lowering of Blood Glucose Improve Cardiovascular Morbidity and Mortality? Nayyar Iqbal* and Arthur H. Rubenstein *Section of Endocrinology, Philadelphia Veterans Affairs
More informationPrevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
More informationDespite the known higher risk of cardiovascular disease
AHA/ADA Scientific Statement Type 1 Diabetes Mellitus and Cardiovascular Disease A Scientific Statement From the American Heart Association and American Diabetes Association Sarah D. de Ferranti, MD, MPH,
More informationDiabetes Care 24: , 2001
Pathophysiology/Complications O R I G I N A L A R T I C L E Prevalence and Significance of Retinopathy in Subjects With Type 1 Diabetes of Less Than 5 Years Duration Screened for the Diabetes Control and
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationMicrovascular Complications
Microvascular Complications in Diabetes Jyotika Fernandes. MD Professor Div of Endocrinology Endo Section Chief, RHJ VA Hospital Microvascular Complications Hyperglycemia Eye Kidney Nerves Retinopathy
More informationFOR PERSONAL USE ONLY
J. Endocrinol. Invest. 36: 574-578, 2013 DOI: 10.3275/8850 Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients T. Bulum 1, B. Kolarić
More informationAccording to the US Renal Data System,
DIABETIC NEPHROPATHY * Mohamed G. Atta, MD ABSTRACT *Based on a presentation given by Dr Atta at a CME dinner symposium for family physicians. Assistant Professor of Medicine, Division of Nephrology, Johns
More informationSource of effectiveness data The effectiveness data were derived from a review or synthesis of completed studies.
Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Dong F B, Sorensen S W, Manninen D L, Thompson T J, Narayan V, Orians C E, Gregg E W, Eastman R C, Dasbach E J,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationComparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes
Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Joshua A Salomon, Anushka Patel, Bruce Neal, Paul Glasziou, Diederick E. Grobbee,
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationRetinal vessel calibre and micro- and macrovascular complications in type 1 diabetes
Diabetologia (2009) 52:2213 2217 DOI 10.1007/s00125-009-1459-8 SHORT COMMUNICATION Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes J. Grauslund & L. Hodgson & R. Kawasaki
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationT1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center
T1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center T1D Exchange Mission and Goals Improve outcomes of people touched
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationDiabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
More information